Research ArticleSystemic Lupus Erythematosus
Mammalian Target of Rapamycin Pathway Assessment in Antiphospholipid Antibody–Positive Patients with Livedo
Ecem Sevim, Salma Siddique, Madhavi Latha S. Chalasani, Susan Chyou, William D. Shipman, Orla O’Shea, Joanna Harp, Oral Alpan, Stéphane Zuily, Theresa T. Lu and Doruk Erkan
The Journal of Rheumatology September 2022, 49 (9) 1026-1030; DOI: https://doi.org/10.3899/jrheum.220049
Ecem Sevim
1E. Sevim, MD, Department of Rheumatology, Hospital for Special Surgery, New York, and Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA;
Salma Siddique
2S. Siddique, DO, Pediatric Rheumatology, Hospital for Special Surgery, New York, New York, now with Nemours Alfred I. DuPont Hospital for Children, Wilmington, Delaware, USA;
Madhavi Latha S. Chalasani
3M.L.S. Chalasani, PhD, T.T. Lu, MD, PhD, Pediatric Rheumatology, Hospital for Special Surgery, Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, and Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York, USA;
Susan Chyou
4S. Chyou, BA, O. O’Shea, MS, Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, New York, USA;
William D. Shipman
5W.D. Shipman, BS, Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, and Weill Cornell Tri-Institutional MD-PhD Program, New York, New York, USA;
Orla O’Shea
4S. Chyou, BA, O. O’Shea, MS, Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, New York, New York, USA;
Joanna Harp
6J. Harp, MD, Department of Dermatology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, New York, USA;
Oral Alpan
7O. Alpan, MD, O&O Alpan, LLC, Fairfax, Virginia, USA;
Stéphane Zuily
8S. Zuily, MD, MPH, PhD, CHRU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, and Inserm U1116 at Lorraine University, Nancy, France;
Theresa T. Lu
3M.L.S. Chalasani, PhD, T.T. Lu, MD, PhD, Pediatric Rheumatology, Hospital for Special Surgery, Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute, and Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York, USA;
Doruk Erkan
9D. Erkan, MD, MPH, Department of Rheumatology, Hospital for Special Surgery, and Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery and Weill Cornell Medicine, New York, NY, USA.

Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 49, Issue 9
1 Sep 2022
Mammalian Target of Rapamycin Pathway Assessment in Antiphospholipid Antibody–Positive Patients with Livedo
Ecem Sevim, Salma Siddique, Madhavi Latha S. Chalasani, Susan Chyou, William D. Shipman, Orla O’Shea, Joanna Harp, Oral Alpan, Stéphane Zuily, Theresa T. Lu, Doruk Erkan
The Journal of Rheumatology Sep 2022, 49 (9) 1026-1030; DOI: 10.3899/jrheum.220049
Mammalian Target of Rapamycin Pathway Assessment in Antiphospholipid Antibody–Positive Patients with Livedo
Ecem Sevim, Salma Siddique, Madhavi Latha S. Chalasani, Susan Chyou, William D. Shipman, Orla O’Shea, Joanna Harp, Oral Alpan, Stéphane Zuily, Theresa T. Lu, Doruk Erkan
The Journal of Rheumatology Sep 2022, 49 (9) 1026-1030; DOI: 10.3899/jrheum.220049